Haplo-HSCT for Myelofibrosis
Key claim: A novel haploidentical stem-cell transplant regimen for myelofibrosis is being investigated in a prospective trial to expand curative access when matched donors are limited despite higher historical graft-failure and TRM risk.
Abstract
Myelofibrosis (MF) is a myeloproliferative neoplasm causing bone marrow failure and high risk of leukemia transformation. JAK2 inhibitors improve symptoms but do not cure MF. Allogeneic stem cell transplantation (allo-HSCT) is the only potential cure, though limited donor availability restricts access. Haploidentical transplantation shows promise but associated with higher graft failure and treatment related mortality. We recently developed a novel regimen of haplo-SCT for MF. This study aims to investigate this novel protocol in a prospective trial to improve MF outcomes.
Why this matters
A novel haploidentical stem-cell transplant regimen for myelofibrosis is being investigated in a prospective trial to expand curative access when matched donors are limited despite higher historical graft-failure and TRM risk.